OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
Angioletta Lasagna, Daniele Lilleri, Francesco Agustoni, et al.
ESMO Open (2021) Vol. 7, Iss. 1, pp. 100359-100359
Open Access | Times Cited: 16
Angioletta Lasagna, Daniele Lilleri, Francesco Agustoni, et al.
ESMO Open (2021) Vol. 7, Iss. 1, pp. 100359-100359
Open Access | Times Cited: 16
Showing 16 citing articles:
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 92
Susan DeWolf, Justin Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 92
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100458-100458
Open Access | Times Cited: 24
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100458-100458
Open Access | Times Cited: 24
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections
Natalia Egri, Hugo Calderón, Robert Martinez, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Natalia Egri, Hugo Calderón, Robert Martinez, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
Paolo Pedrazzoli, Angioletta Lasagna, Irene Cassaniti, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101215-101215
Open Access | Times Cited: 12
Paolo Pedrazzoli, Angioletta Lasagna, Irene Cassaniti, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101215-101215
Open Access | Times Cited: 12
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
Emanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 273-273
Open Access
Emanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 273-273
Open Access
Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial
Radka Obermannová, Iveta Selingerová, Regina Demlová, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Radka Obermannová, Iveta Selingerová, Regina Demlová, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100574-100574
Open Access | Times Cited: 15
Angioletta Lasagna, Federica Bergami, Daniele Lilleri, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100574-100574
Open Access | Times Cited: 15
Clinical efficacy of the first two doses of anti‐SARS‐CoV ‐2 mRNA vaccines in solid cancer patients
Maria Silvia Cona, Agostino Riva, Davide Dalu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 12967-12974
Open Access | Times Cited: 6
Maria Silvia Cona, Agostino Riva, Davide Dalu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 12967-12974
Open Access | Times Cited: 6
Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges
Muna Almasri, Khalifa Bshesh, Wafa Khan, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5630-5630
Open Access | Times Cited: 9
Muna Almasri, Khalifa Bshesh, Wafa Khan, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5630-5630
Open Access | Times Cited: 9
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
Fabrizio Nelli, Agnese Fabbri, Valentina Panichi, et al.
International Immunopharmacology (2022) Vol. 108, pp. 108774-108774
Open Access | Times Cited: 8
Fabrizio Nelli, Agnese Fabbri, Valentina Panichi, et al.
International Immunopharmacology (2022) Vol. 108, pp. 108774-108774
Open Access | Times Cited: 8
Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
Marta Sisteré‐Oró, Diana D. J. Wortmann, Naína Andrade, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4
Marta Sisteré‐Oró, Diana D. J. Wortmann, Naína Andrade, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4
Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report
Shreya Tripathy, Nathaniel Alvarez, Shubham Jaiswal, et al.
Journal of Medical Case Reports (2022) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Shreya Tripathy, Nathaniel Alvarez, Shubham Jaiswal, et al.
Journal of Medical Case Reports (2022) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
Shanshan Han, Yuping Yang, Tingrui Wang, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 2
Shanshan Han, Yuping Yang, Tingrui Wang, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 2
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects
Giulia Brisotto, Marcella Montico, Matteo Turetta, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1276-1276
Open Access | Times Cited: 2
Giulia Brisotto, Marcella Montico, Matteo Turetta, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1276-1276
Open Access | Times Cited: 2
Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders
Ryousuke Kasai, Michinori Funato, Kanako Maruta, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Ryousuke Kasai, Michinori Funato, Kanako Maruta, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1
Serological response and immune‐related adverse events following COVID‐19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis
Yue Wang, Dong Chen, Yuancan Pan, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Closed Access | Times Cited: 1
Yue Wang, Dong Chen, Yuancan Pan, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Closed Access | Times Cited: 1
COVID-19 Vaccination and Cancer: The Most Critical Issues
Elahe Esmaeili, Tooba Ghazanfari
Immunoregulation (2022) Vol. 5, Iss. 1, pp. 25-38
Open Access
Elahe Esmaeili, Tooba Ghazanfari
Immunoregulation (2022) Vol. 5, Iss. 1, pp. 25-38
Open Access
